Andrea Apolo | |
|---|---|
 | |
| Alma mater | Lehman College (BS) Albert Einstein College of Medicine (MD) |
| Scientific career | |
| Fields | Medical oncology, clinical trials |
| Institutions | National Cancer Institute |
Andrea B. Apolo is an American medical oncologist specialized in bladder cancer research. She is an investigator in the National Cancer Institute's genitourinary malignancies branch and head of the bladder cancer section.
Apolo graduated summa cum laude from Lehman College with a Bachelor of Science in chemistry and biochemistry. She earned her medical degree at Albert Einstein College of Medicine. Apolo completed residency training in internal medicine at New York-Presbyterian Hospital and then completed a medical oncology fellowship at Memorial Sloan Kettering Cancer Center. [1] [2]
In 2010, she was recruited to the National Cancer Institute’s (NCI) Physician-Scientist Early Investigator Program to build a translational bladder cancer program. Apolo serves within the Center for Cancer Research of the National Cancer Institute as Head of the Bladder Cancer Section of the Genitourinary Malignancies Branch and Director of the Bladder Cancer and Genitourinary Tumors Multidisciplinary Clinic. [1]
Apolo serves on national and National Institutes of Health committees. She has been an investigator on over 35 clinical trials and authored more than 80 scientific papers or chapters which have been cited over 1,800 times. She serves on a number of editorial boards, and has made over 100 scientific presentations at universities and national/international meetings. [1]
Apolo designs and implements clinical trials to test novel agents for the treatment of urologic cancers. Her research focuses on developing targeted therapies for bladder cancer and rare genitourinary tumors, including immunotherapies, angiogenesis inhibitors, and agents that target MET, and in identifying molecular alterations that will serve as targets for individualized treatment strategies. Apolo manages clinical development of immunotherapeutic agents and immunotherapeutic combinations in cancer and genitourinary tumors. She led the bladder cancer study of avelumab that resulted in FDA approval in advanced bladder cancer. [1]
Apolo received a 2011 National Institutes of Health Award of Merit, the 2014 Lasker Clinical Research Scholars Program Award, the 2018 National Cancer Institute's Director's Award for Clinical Science, the 2018 Advancing Cancer Treatment Award for leadership in genitourinary clinical trial patient access, and the 2020 Arthur S. Flemming Award for leaders who make an impact in public service. [1] She was also recognized as one of the 100 Influential Women in Oncology by OncoDaily. [3]
Nicholas J. Vogelzang was a medical oncologist with Comprehensive Cancer Centers of Nevada (CCCN). He serves as medical director of the Research Executive Committee and Associate Chair of the Developmental Therapeutics and Genitourinary Committees for US Oncology Research. His research interests include clinical trials for genitourinary malignancies and mesothelioma.
Cancer and Leukemia Group B is a cancer research cooperative group in the United States.
Oncology is a branch of medicine that deals with the study, treatment, diagnosis and prevention of cancer. A medical professional who practices oncology is an oncologist. The name's etymological origin is the Greek word ὄγκος (ónkos), meaning "tumor", "volume" or "mass". Oncology is concerned with:
Hope & Heroes is a 501(c)(3) non-profit organization based at Columbia University Medical Center (CUMC) in New York City. Hope & Heroes supports the Division of Pediatric Hematology, Oncology & Stem Cell Transplantation at Columbia University Medical Center. Hope & Heroes funds work on childhood cancer and blood disorders at Columbia University Medical Center—including research, support for families, and care.
Larry Kwak is an American cancer researcher who works at City of Hope in Duarte, California and is the Director of the Toni Stephenson Lymphoma Center at City of Hope. Dr. Kwak formerly worked at the University of Texas MD Anderson Cancer Center. He was included on Time's list of 2010's most influential people.
Wolfram Samlowski is an American medical oncologist with Comprehensive Cancer Centers of Nevada (CCCN) and a member of the Research Developmental Therapeutics and Genitourinary Committees for US Oncology. His research interests include translational research and development of novel cancer immunotherapy agents, translational drug development as well as gene therapy. His clinical interests are in developing more effective treatments for advanced stages of melanoma and non-melanoma skin cancers, and renal cancer.
George Bosl is an American cancer researcher, holder of the Patrick M. Byrne Chair in Clinical Oncology at the Memorial Sloan-Kettering Cancer Center in New York City, and is a professor of medicine at the Weill Cornell Medical College. In 1997, he was appointed chair of the Department of Medicine at Sloan-Kettering, a position which he held until 2015. In 2019, he was named Memorial Sloan Kettering's first ombudsperson.
Professor Minesh P. Mehta, MD, FASTRO, is an American radiation oncologist and physician-scientist of Indian origin, Ugandan birth, Zambian Schooling and American Training, who contributed to the field of oncology for more than two and half decades.
Dr. Cora Sternberg is an American medical oncologist at Weill Cornell Medicine and NewYork-Presbyterian Hospital, serving as a member of the Genitourinary (GU) Oncology Program. Dr. Sternberg facilitates the continued growth and development of clinical and translational research programs in GU malignancies. Dr. Sternberg is an internationally respected leader in the field of medical oncology and urological malignancies and a recognized expert in the area of new drug development. She is known for her seminal contributions in bladder cancer, her strong track record of sustained genito-urinary (GU) oncology leadership and collaboration in multiple practice-changing clinical trials, including novel medicines, and her current role applying her expertise in oncology and GU cancers to precision medicine to further improve outcomes for patients. Dr. Sternberg has been decidedly influential in the development of novel hormonal therapies and checkpoint inhibitors across the landscape of GU oncology as evidenced in her curriculum vitae. She is a globally respected researcher who has lectured extensively at universities and cancer symposia worldwide (>800). As Clinical Director of the Englander Institute for Precision Medicine (EIPM), Dr. Sternberg develops strategies to incorporate genomic sequencing and precision medicine throughout the Weill Cornell Medicine and NewYork-Presbyterian healthcare network, including Lower Manhattan, Brooklyn and Queens.
Waun Ki Hong was Professor of Medicine at The University of Texas MD Anderson Cancer Center, where he served as chairman of the Department of Thoracic/Head & Neck Medical Oncology from 1993 to 2005 and as head of the Division of Cancer Medicine from 2001 to 2014. He was also an American Cancer Society Professor and the Samsung Distinguished University Chair in Cancer Medicine emeritus.
Hua Eleanor Yu is the inaugural Billy and Audrey L. Wilder Professor in tumor immunotherapy at the Beckman Research Institute of the City of Hope National Medical Center in Duarte, California. In addition, she co-leads the Cancer Immunotherapeutics Program at the City of Hope cancer center, with Peter P. Lee. Yu's laboratory was the first to identify STAT3, a protein that helps to protect tumor cells from the immune system. Her group is developing possible drug treatments using CpG-Stat3 siRNA to attack tumor cells in mice and humans.
Holger Lode is a German specialist for pediatrics. He is Professor and Chair of the Department of General Pediatrics and Pediatric Hematology and Oncology at the University Medicine Greifswald. He is also the director of the Center of Pediatrics and Adolescent Medicine in Greifswald. Lode is well known for his clinical and scientific work on immunotherapy of neuroblastoma.
Thomas E. Hutson is an American medical oncologist and cancer researcher based in Dallas, Texas. He is the director of Genitourinary Oncology Program and co-director of the Urologic Cancer Research and Treatment Center at Baylor University Medical Center. He is a Professor of Medicine at the Texas A&M Health Science Center College of Medicine and serves as a chair of Genitourinary Research for US Oncology and McKesson.
Elizabeth M. Jaffee is an American oncologist specializing in pancreatic cancer and immunotherapy.
Padmanee Sharma is an immunologist and oncologist at the University of Texas MD Anderson Cancer Center in Houston, Texas. She holds the position of professor of genitourinary medical oncology and immunology in the Division of Cancer Medicine where she specializes in renal, prostate, and bladder cancers.
Pamela Lyn Kunz is an American oncologist. She is the leader of the Gastrointestinal Cancers Program at Yale Cancer Center and Smilow Cancer Hospital and director of GI Medical Oncology within the Section of Medical Oncology. She was formerly the director of the Stanford Neuroendocrine Tumor Program before leaving, in part due to gender harassment. Kunz was also recognized as one of the 100 Influential Women in Oncology by OncoDaily.
Jung-Min Lee is a South Korean-American medical oncologist and physician-scientist focused on the early clinical drug development and translational studies of targeted agents in BRCA mutation-associated breast or ovarian cancer, high-grade epithelial ovarian cancer, and triple-negative breast cancer. She is a NIH Lasker Clinical Research Scholar and principal investigator in the Women's Malignancies Branch at the National Cancer Institute.
Catherine J. Wu is an American physician-scientist who studies oncology. She is a Professor of Medicine and Chief of Division of Stem Cell Transplantation and Cellular Therapies at the Dana–Farber Cancer Institute. Her research focuses on longitudinal studies of patients with chronic lymphocytic leukemia (CLL).
Nirali N. Shah is an American physician-scientist and pediatric hematologist-oncologist, serving as head of the hematologic malignancies section of the pediatric oncology branch at the National Cancer Institute. She researches the translation of immunotherapeutic approaches to treat high-risk hematologic malignancies in children, adolescents and young adults.
Elizabeth R. Plimack is an American medical oncologist. She is a professor in the Department of Hematology/Oncology and Chief of the Division of Genitourinary Medical Oncology at the Fox Chase Cancer Center. In these roles, she researches the treatment of genitourinary malignancies with a focus on bladder and kidney cancers.
This article incorporates text from this source, which is in the public domain . This article incorporates text from this source, which is in the public domain .| International | |
|---|---|
| National | |
| Academics | |
